OVER DEZE AFLEVERING
In this episode of The BioHub Podcast by Avetix, Ben O’Keefe sits down with Nick Sireau, Executive Chairman and Co-Founder of Serenatis Bio, to discuss the company’s mission to develop a new generation of treatments for obsessive-compulsive disorder (OCD).
Nick shares the deeply personal story behind Serenatis, from his own experience living with OCD to the loss of a close friend to the condition, and how that ultimately helped shape the company’s focus.
They explore why OCD remains a significantly underserved area of neuropsychiatry, what the biology of compulsivity can teach us more broadly, and Serenatis’ approach to developing novel mechanisms targeting glutamate, neuroinflammation and dopamine-related pathways.
Nick also discusses the company’s lead programme, plans to enter Phase 1b development, the role neuroimaging could play in demonstrating early proof of biology, and what Serenatis is aiming to achieve over the next 18 months.
A fascinating conversation on building a neuroscience company around both strong biology and a very personal mission.
